David Ransom

3.7k total citations
36 papers, 1.3k citations indexed

About

David Ransom is a scholar working on Oncology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Ransom has authored 36 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 11 papers in Epidemiology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Ransom's work include Neuroendocrine Tumor Research Advances (10 papers), Lung Cancer Research Studies (8 papers) and RNA modifications and cancer (5 papers). David Ransom is often cited by papers focused on Neuroendocrine Tumor Research Advances (10 papers), Lung Cancer Research Studies (8 papers) and RNA modifications and cancer (5 papers). David Ransom collaborates with scholars based in Australia, United States and United Kingdom. David Ransom's co-authors include David W. Kimmel, Erin O’Brien, Jeffrey A. Moscow, Harry S. Wieand, David G. Poplack, Mary Madden, Craig R. Fairchild, Jeffrey Cossman, Kenneth H. Cowan and Charles E. Myers and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

David Ransom

36 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Ransom Australia 18 583 524 306 220 185 36 1.3k
Martha G. Sensel United States 24 603 1.0× 438 0.8× 262 0.9× 169 0.8× 93 0.5× 42 2.8k
Sílvia Regina Brandalise Brazil 23 813 1.4× 408 0.8× 193 0.6× 425 1.9× 189 1.0× 91 1.8k
E.J. Shpall United States 19 254 0.4× 564 1.1× 326 1.1× 209 0.9× 218 1.2× 48 1.4k
Gisele W. B. Colleoni Brazil 21 678 1.2× 590 1.1× 152 0.5× 165 0.8× 185 1.0× 85 1.5k
Yasuyuki Hirashima Japan 26 557 1.0× 542 1.0× 123 0.4× 406 1.8× 184 1.0× 81 1.8k
Niall Swan Ireland 18 702 1.2× 453 0.9× 152 0.5× 102 0.5× 248 1.3× 59 1.4k
Loretta M. S. Lau Australia 21 593 1.0× 293 0.6× 119 0.4× 148 0.7× 169 0.9× 52 1.3k
Julie Irving United Kingdom 28 772 1.3× 388 0.7× 104 0.3× 293 1.3× 358 1.9× 66 2.8k
Pedro Pérez‐Segura Spain 18 407 0.7× 467 0.9× 194 0.6× 294 1.3× 237 1.3× 117 1.2k
W. Paul Bowman United States 26 348 0.6× 336 0.6× 325 1.1× 126 0.6× 218 1.2× 50 2.1k

Countries citing papers authored by David Ransom

Since Specialization
Citations

This map shows the geographic impact of David Ransom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Ransom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Ransom more than expected).

Fields of papers citing papers by David Ransom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Ransom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Ransom. The network helps show where David Ransom may publish in the future.

Co-authorship network of co-authors of David Ransom

This figure shows the co-authorship network connecting the top 25 collaborators of David Ransom. A scholar is included among the top collaborators of David Ransom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Ransom. David Ransom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chantrill, Lorraine A., David Ransom, David Chan, et al.. (2024). NABNEC: A randomised phase II study of nab -paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas (GI-NECs).. Journal of Clinical Oncology. 42(3_suppl). 589–589. 2 indexed citations
2.
Gough, Karla, Allison Drosdowsky, Timothy Price, et al.. (2023). The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis. Supportive Care in Cancer. 31(10). 577–577. 1 indexed citations
3.
Cabasag, Citadel J., Melina Arnold, Mark J. Rutherford, et al.. (2022). Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study. British Journal of Cancer. 126(12). 1774–1782. 25 indexed citations
4.
5.
Elston, Marianne S., Dev Kevat, Richard Carroll, et al.. (2021). Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours. Cancer Medicine. 10(23). 8405–8411. 7 indexed citations
6.
7.
Girschik, Jennifer, Laura Miller, Mike Daube, et al.. (2017). Precision in Setting Cancer Prevention Priorities: Synthesis of Data, Literature, and Expert Opinion. Frontiers in Public Health. 5. 125–125. 4 indexed citations
8.
Schofield, Penelope, Martin R. Stockler, Diana Zannino, et al.. (2015). Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer. Supportive Care in Cancer. 24(1). 401–408. 32 indexed citations
9.
Ransom, David, Kate Wilson, Marion Fournier, et al.. (2013). Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Annals of Oncology. 25(1). 117–121. 49 indexed citations
10.
Clarke, Stephen, Sonia Yip, Chris Brown, et al.. (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer. 47(12). 1826–1836. 17 indexed citations
11.
Morris, M. J., Cameron Platell, Kieran McCaul, et al.. (2007). Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. International Journal of Colorectal Disease. 22(8). 887–895. 33 indexed citations
12.
Ransom, David. (2002). Comercio justo: doble comercio. Dialnet (Universidad de la Rioja). 2 indexed citations
13.
Ransom, David, et al.. (1998). Loss of heterozygosity on chromosome 2q: Possibly a poor prognostic factor in head and neck cancer. Head & Neck. 20(5). 404–410. 41 indexed citations
14.
Ganju, Vinod, Robert B. Jenkins, Judith R. OʼFallon, et al.. (1994). Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer. 74(3). 920–927. 71 indexed citations
15.
Ransom, David, Cheryl A. Moertel, Richard J. Dahl, et al.. (1992). Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo‐astrocytomas. Genes Chromosomes and Cancer. 5(4). 357–374. 105 indexed citations
16.
Ransom, David, S Ritland, David W. Kimmel, et al.. (1992). Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosomes and Cancer. 5(4). 348–356. 150 indexed citations
17.
Ransom, David, Donna Neuberg, Charles L. Loprinzi, et al.. (1991). A Pilot Study of Three Sequential Chemotherapeutic Regimens in Metastatic Breast Cancer. American Journal of Clinical Oncology. 14(1). 45–48. 3 indexed citations
18.
Ransom, David, Shreyaskumar Patel, Gary L. Keeney, George D. Malkasian, & John H. Edmonson. (1990). Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer. 66(6). 1091–1094. 88 indexed citations
19.
Ransom, David, Robert P. Dinapoli, & Ronald L. Richardson. (1990). Cranial nerve lesions due to base of the skull metastases in prostate carcinoma. Cancer. 65(3). 586–589. 38 indexed citations
20.
Ransom, David & F Cameron. (1987). Scleroderma – A Possible Contra‐Indication to Lumpectomy and Radiotherapy in Breast Carcinoma. Australasian Radiology. 31(3). 317–318. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martha G. Sensel Breakdown of academic impact, for papers by Sílvia Regina Brandalise Breakdown of academic impact, for papers by E.J. Shpall Breakdown of academic impact, for papers by Gisele W. B. Colleoni Breakdown of academic impact, for papers by Yasuyuki Hirashima Breakdown of academic impact, for papers by Niall Swan Breakdown of academic impact, for papers by Loretta M. S. Lau Breakdown of academic impact, for papers by Julie Irving Breakdown of academic impact, for papers by Pedro Pérez‐Segura Breakdown of academic impact, for papers by W. Paul Bowman
Rankless by CCL
2026